SynthesisFrontiers in immunology2026
Global research trends and thematic evolution in neoadjuvant therapy and surgery for non-small cell lung cancer: a bibliometric and scientometric analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant therapy has become a cornerstone of curative-intent management for resectable non-small cell lung cancer (NSCLC), particularly since immune checkpoint inhibitors and biomarker-guided strategies entered perioperative practice. However, the field's global knowledge structure, collaboration architecture, and surgery-relevant thematic transitions have not been comprehensively mapped. Methods: Publications on neoadjuvant/induction/preoperative therapy and surgery for NSCLC (January 1989 to September 2025) were retrieved from the Web of Science Core Collection, PubMed, and Wanfang. Bibliometrix, VOSviewer, and CiteSpace were used to quantify productivity and impact, map collaboration and coupling networks, and identify co-citation clusters and citation/keyword bursts. Latent Dirichlet Allocation (LDA; k=8) was applied to abstracts and keywords to characterize semantic domains and their evolution. Results: A total of 1,512 publications were included. China and the United States were the dominant contributors and citation hubs. European countries showed higher proportions of multinational collaborations. Core journals formed a dual source landscape bridging thoracic surgery and oncology/immunology. Co-citation clustering showed strong structural validity and highlighted the rise of neoadjuvant chemoimmunotherapy, perioperative safety, and pathological response endpoints. LDA confirmed a shift from induction chemotherapy/chemoradiotherapy toward immunotherapy-centered perioperative paradigms and translational monitoring. Surgery-facing synthesis of representative landmark studies emphasized evolving emphases on complete resection, downstaging, and lung-sparing operative strategies. Conclusions: From January 1989 to September 2025, neoadjuvant NSCLC research transitioned from cytotoxic induction to immunologically driven, biomarker-informed perioperative paradigms tightly integrated with surgery. This integrated bibliometric-semantic framework provides a reproducible approach to monitor emerging fronts and to translate research signals into clinically interpretable questions for multidisciplinary perioperative decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.